Medical Condition News

RSS

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that its new oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules, will be available starting Wednesday by prescription in pharmacies across the United States, including CVS/pharmacy, Rite Aid, Walmart, Target, Kmart® and The Kroger Co. In addition, leading independents under the Health Mart®, Good Neighbor Pharmacy® and Medicine Shoppe® banners will be stocked.

2 Nov 2010

Long-term cell phone usage doubles risk of developing brain tumors

The highest-quality research data available suggests that long-term exposure to microwaves from cellular phones may lead to an increased risk of brain tumors, reports a paper in the November/December issue of Journal of Computer Assisted Tomography. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

2 Nov 2010

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).

2 Nov 2010

ISHIB releases new recommendations to manage hypertension in African Americans

Through the publication of its Consensus Statement on the Management of High Blood Pressure in Blacks in this week's issue of Hypertension, ISHIB today released new recommendations recognizing that high blood pressure among African Americans is a severe health problem. The consensus statement suggests that treatment should start sooner and be more aggressive among African Americans.

2 Nov 2010

Fat filling for facial rejuvenation

Aging will affect all of us. Fillers are most commonly used to fill the deep lines around the mouth. Dr. Hardaway, a prominent Farmington Hills, Michigan plastic surgeon states that many patients now prefer to have their own fat injected to fill those unwanted wrinkles.

2 Nov 2010

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.

2 Nov 2010

Study finds invasive patterns of lung cancer in pediatric patients

Because primary lung adenocarcinoma is exceedingly rare in the pediatric population, it is difficult to properly classify certain lung tumors in children and adolescents. While anecdotal reports of pediatric patients with lung cancer lesions exist, little research has been conducted to link the disease in children to similar pulmonary malignancies in adults.

2 Nov 2010

FDA approves Medtronic Talent Thoracic Stent Graft with Captivia Delivery System

Advancing the minimally invasive treatment of aortic aneurysms, Medtronic, Inc. (NYSE: MDT), today announced approval by the U.S. Food and Drug Administration (FDA) of the Talent Thoracic Stent Graft with Captivia® Delivery System, which features a tip capture mechanism for controlled deployment and precise placement of the implantable medical device.

2 Nov 2010

New findings pave way to improve early detection of ovarian cancer

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

2 Nov 2010

Non-dividing cells can also start cancer

Cancer Research UK scientists have found that non-dividing cells are able to kick-start some cancers, challenging a long held belief that only dividing cells, like stem cells, cause the disease, according to research published online in PNAS today (Monday).

2 Nov 2010

National Jewish Health's chronic urticaria diagnostic assay receives US patent

National Jewish Health has received a US patent for a method of detecting autoimmune chronic urticaria, which will help assure many patients that dramatic changes in lifestyle are not needed to treat the condition.

2 Nov 2010

XXXXL suits now on the racks: UK health experts concerned

In a worrying development Britain’s largest ‘off-the-peg’ suit - the XXXXL - has gone on sale, boasting a 64 inch chest jacket and 60 inch waist trousers. Health experts fear the development and say that a record 5.5 million overweight Britons are now officially on GP registers with an eight percent rise over last year.

1 Nov 2010

Physical activity outside of work reduces risk of depression: Study

Researchers have found evidence that regular exercise reduces the risk of depression provided the activity is carried out in leisure time. People who exert themselves at work, for instance by digging up roads or heavy lifting, were no less likely to suffer depression than those in sedentary desk jobs.

1 Nov 2010

IMRT safe and effective treatment for paranasal tumors: Study

Treating paranasal sinus cancer with three-dimensional radiation that conforms to the shape of the tumor-a technique that minimizes side effects such as severe dry mouth and vision problems-is safe and effective, research at Fox Chase Cancer Center shows. Aruna Turaka, M.D., radiation oncologist at Fox Chase, will present the results on November 2nd at the annual meeting of the American Society for Radiation Oncology.

1 Nov 2010

Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.

1 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

BSD MTX-180 MicroThermX Microwave Ablation System receives CE Mark approval

BSD Medical Corporation, the company that pioneered heat therapy applications, today reported that the Company has received CE Mark approval for the commercial sale of The MicroThermX Microwave Ablation System (MTX-180) in Europe. CE marking approval allows BSD to market the MTX-180 in the 30 countries that comprise the European Union (EU) and the European Free Trade Association (EFTA).

1 Nov 2010

Gore announces new Early TIPS for Ascites Study

W.L. Gore & Associates (Gore) today announced a new prospective, randomized, multi-center study at the Annual Meeting of the American Association for the Study of Liver Diseases. The hypothesis of the study is that early intervention with the GORE® VIATORR® TIPS Endoprosthesis improves transplant-free survival when compared to large volume paracentesis in patients with cirrhosis and difficult to treat ascites.

1 Nov 2010

Varian's Acuros XB dose calculation algorithm for radiotherapy receives FDA 510(k) clearance

Varian Medical Systems has received FDA 510(k) clearance for the Acuros® XB advanced dose calculation algorithm which can complete a RapidArc® treatment plan two to three times faster than conventional planning algorithms. Varian has incorporated the Acuros algorithm for external beam radiotherapy treatment planning into its market-leading Eclipse™ treatment planning system on exhibit at the 52nd annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego October 31 - November 4.

1 Nov 2010

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.

1 Nov 2010